TY - JOUR
T1 - Metabolic Dysfunction-Associated Steatotic Liver Disease in Severe Obesity and Concordance between Invasive (Biopsy) and Noninvasive (OWLiver®) Diagnoses
AU - Navarro-Masip, Èlia
AU - Mestres Petit, Nuria
AU - Salinas-Roca, Blanca
AU - Herrerías, Fernando
AU - Vilardell, Felip
AU - de la Fuente, Mari Cruz
AU - Pallares, Judit
AU - Santamaría, Maite
AU - Zorzano-Martínez, Marta
AU - Sánchez, Enric
AU - Matías-Guiu, Xavier
AU - López-Cano, Carolina
AU - Soler, Ana Gloria
AU - León-Mengíbar, Josep
AU - Bueno, Marta
AU - Lecube, Albert
N1 - Publisher Copyright:
© 2024 The Author(s). Published by S. Karger AG, Basel.
PY - 2024/6/26
Y1 - 2024/6/26
N2 - Introduction: Nonalcoholic fatty liver disease (NAFLD), now termed metabolic dysfunction-associated steatotic liver disease (MASLD), is an escalating health concern linked to obesity and type 2 diabetes. Despite liver biopsy being the gold standard, its invasiveness underscores the need for noninvasive diagnostic methods. Methods: A cross-sectional study was performed to assess MASLD using the noninvasive OWLiver
® serum lipidomics test in a cohort of 117 patients with severe obesity undergoing bariatric surgery, comparing outcomes with liver biopsy. Exclusions (n = 24) included insufficient data, liver disease etiology other than MASLD, corticosteroid treatment, excessive alcohol consumption, low glomerular filtration rate, and declination to participate. Comprehensive laboratory tests, demographic assessments, and liver biopsies were performed. Serum metabolites were analyzed using OWLiverR, a serum lipidomic test that discriminates between healthy liver, steatosis, metabolic dysfunction-associated steatohepatitis (MASH), and MASH with fibrosis ≥2 by means of three algorithms run sequentially. Results: Liver biopsy revealed a MASLD prevalence of 95.7%, with MASH present in 28.2% of cases. OWLiverR demonstrated a tendency to diagnose more severe cases. Body mass index (BMI), rather than the presence of type 2 diabetes, emerged as the sole independent factor linked to the probability of concordance. Therefore, the all-population concordance of 63.2% between OWLiver
® and liver biopsy notably raised to 77.1% in patients with a BMI <40 kg/m
2. These findings suggest a potential correlation between lower BMI and enhanced concordance between OWLiver
® and biopsy. Conclusion: This study yields valuable insights into the concordance between liver biopsy and the noninvasive serum lipidomic test, OWLiver
®, in severe obesity. OWLiver
® demonstrated a tendency to amplify MASLD severity, with BMI values influencing concordance. Patients with BMI <40 kg/m2 may derive optimal benefits from this noninvasive diagnostic approach.
AB - Introduction: Nonalcoholic fatty liver disease (NAFLD), now termed metabolic dysfunction-associated steatotic liver disease (MASLD), is an escalating health concern linked to obesity and type 2 diabetes. Despite liver biopsy being the gold standard, its invasiveness underscores the need for noninvasive diagnostic methods. Methods: A cross-sectional study was performed to assess MASLD using the noninvasive OWLiver
® serum lipidomics test in a cohort of 117 patients with severe obesity undergoing bariatric surgery, comparing outcomes with liver biopsy. Exclusions (n = 24) included insufficient data, liver disease etiology other than MASLD, corticosteroid treatment, excessive alcohol consumption, low glomerular filtration rate, and declination to participate. Comprehensive laboratory tests, demographic assessments, and liver biopsies were performed. Serum metabolites were analyzed using OWLiverR, a serum lipidomic test that discriminates between healthy liver, steatosis, metabolic dysfunction-associated steatohepatitis (MASH), and MASH with fibrosis ≥2 by means of three algorithms run sequentially. Results: Liver biopsy revealed a MASLD prevalence of 95.7%, with MASH present in 28.2% of cases. OWLiverR demonstrated a tendency to diagnose more severe cases. Body mass index (BMI), rather than the presence of type 2 diabetes, emerged as the sole independent factor linked to the probability of concordance. Therefore, the all-population concordance of 63.2% between OWLiver
® and liver biopsy notably raised to 77.1% in patients with a BMI <40 kg/m
2. These findings suggest a potential correlation between lower BMI and enhanced concordance between OWLiver
® and biopsy. Conclusion: This study yields valuable insights into the concordance between liver biopsy and the noninvasive serum lipidomic test, OWLiver
®, in severe obesity. OWLiver
® demonstrated a tendency to amplify MASLD severity, with BMI values influencing concordance. Patients with BMI <40 kg/m2 may derive optimal benefits from this noninvasive diagnostic approach.
KW - Liver
KW - Metabolic dysfunction-associated steatohepatitis
KW - Metabolic dysfunction-associated steatotic liver disease
KW - Obesity
KW - OWLiver®
KW - Steatohepaitis
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85206017213&partnerID=8YFLogxK
U2 - 10.1159/000538765
DO - 10.1159/000538765
M3 - Article
C2 - 38934179
AN - SCOPUS:85206017213
SN - 1662-4025
VL - 17
SP - 473
EP - 482
JO - Obesity Facts
JF - Obesity Facts
IS - 5
ER -
